Literature DB >> 2073099

Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase.

F Caron1, L Gutmann, A Bure, B Pangon, J M Vallois, A Pechinot, C Carbon.   

Abstract

We studied the activity of the combination of sulbactam and ceftriaxone against a Klebsiella pneumoniae strain producing TEM-3, a new extended-broad-spectrum beta-lactamase, in an endocarditis model. In vitro, ceftriaxone was strongly inactivated in the presence of TEM-3 (MBC, 128 micrograms/ml with an inoculum of 5 x 10(5) CFU/ml). A marked inoculum effect was demonstrated with sulbactam: effective concentrations of inhibitor needed to reduce the MIC and MBC of ceftriaxone to similar levels increased from 1 microgram/ml in the presence of an inoculum of 5 x 10(5) CFU/ml to 20 micrograms/ml in the presence of an inoculum of 1 x 10(7) CFU/ml. In vivo, sulbactam given at 200 mg/kg of body weight every 12 h, a dosage higher than that previously reported to be effective against rabbit endocarditis caused by other microorganisms, was not sufficient to restore the complete activity of ceftriaxone given at 30 mg/kg once daily for 4 days. This insufficient activity may be correlated with the presence of a high level of beta-lactamase inside the vegetations, as indicated by a quantitative in vitro assay of beta-lactamase activity in the cardiac vegetation, suggesting an insufficient inactivation of the extended-broad-spectrum beta-lactamase in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2073099      PMCID: PMC172001          DOI: 10.1128/AAC.34.11.2070

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Statistics in practice. Comparing the means of several groups.

Authors:  K Godfrey
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

2.  Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase.

Authors:  B Fantin; B Pangon; G Potel; F Caron; E Vallée; J M Vallois; J Mohler; A Buré; A Philippon; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

3.  Pharmacokinetics of sultamicillin in mice, rats, and dogs.

Authors:  A R English; D Girard; S L Haskell
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

4.  6-Acetylmethylenepenicillanic acid (Ro 15-1903), a potent beta-lactamase inhibitor. I. Inhibition of chromosomally and R-factor-mediated beta-lactamases.

Authors:  M Arisawa; R L Then
Journal:  J Antibiot (Tokyo)       Date:  1982-11       Impact factor: 2.649

5.  Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Authors:  H C Neu; N J Meropol; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

6.  Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography.

Authors:  A C Cremieux; B Maziere; J M Vallois; M Ottaviani; A Azancot; H Raffoul; A Bouvet; J J Pocidalo; C Carbon
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

7.  Pharmacokinetics of sulbactam in humans.

Authors:  G Foulds; J P Stankewich; D C Marshall; M M O'Brien; S L Hayes; D J Weidler; F G McMahon
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

8.  Pharmacokinetics and bioavailability of sultamicillin estimated by high performance liquid chromatography.

Authors:  H J ROgers; I D Bradbrook; P J Morrison; R G Spector; D A Cox; L J Lees
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

9.  Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus.

Authors:  R G Washburn; D T Durack
Journal:  J Infect Dis       Date:  1981-09       Impact factor: 5.226

10.  Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart.

Authors:  B B Perlman; L R Freedman
Journal:  Yale J Biol Med       Date:  1971-10
View more
  18 in total

1.  In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.

Authors:  D Szabó; A Máthé; Z Filetóth; P Anderlik; L Rókusz; F Rozgonyi
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 2.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 3.  Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis.

Authors:  A C Cremieux; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 4.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 5.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

6.  Inoculum effect of β-lactam antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

7.  Importance of penicillinase production for activity of penicillin alone or in combination with sulbactam in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  B Fantin; J Pierre; N Castéla-Papin; L Saint-Julien; H Drugeon; R Farinotti; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

8.  Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae.

Authors:  C Thauvin-Eliopoulos; M F Tripodi; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

9.  Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases.

Authors:  G P Katsanis; J Spargo; M J Ferraro; L Sutton; G A Jacoby
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

10.  In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae.

Authors:  L B Rice; L L Carias; D M Shlaes
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.